Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, Inc. reported an equity award to officer Jonathan S. Wolin, who serves as Chief of Staff, Chief Compliance Officer and General Counsel. On December 11, 2025, he received 11,740 shares of common stock in the form of restricted stock units at a price of $0, granted under the company’s 2014 Stock Incentive Plan. These restricted stock units each represent one share of voting common stock and are scheduled to vest on December 11, 2026, with shares delivered on the vesting date as provided in the grant notice.
On the same date, he was also granted a stock option for 11,740 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests ratably on a monthly basis over 12 months from the grant date, contingent on his continued employment. After these grants, he directly beneficially owned 11,938 shares of common stock and options covering 11,740 shares.
Jaguar Health, through its subsidiary Napo Pharmaceuticals, entered a major U.S. license and supply deal for its Mytesi and Canalevia products with Woodward Specialty, an affiliate of Future Pak. Napo granted the licensee exclusive rights to commercialize these products in the United States and will supply finished product under a separate supply agreement.
In return, Napo receives an upfront payment of $18 million, consisting of $16 million paid on January 12, 2026 and a $2 million holdback contingent on specified conditions by the six‑month anniversary of that date, plus potential milestone payments of up to $17 million tied to defined events. Future Pak provides limited guarantees of the licensee’s milestone and supply payment obligations. Starting after the fifth anniversary of the effective date, if Napo secures U.S. FDA approval for additional Mytesi indications and complies with the agreement, it has a unilateral option to buy back all licensed rights by making a contractually defined payment.
Jaguar Health, Inc. filed an amended current report to correct execution, closing, and report dates related to a recent financing agreement, and to replace prior exhibits with corrected versions. On January 6, 2026, the company entered into securities purchase agreements with two accredited investors and issued $350,000 aggregate principal amount of unsecured promissory notes, bearing interest at 6% per annum and maturing one month after issuance. The company may prepay the notes without penalty and plans to use the proceeds for working capital and general corporate purposes. As an inducement, the investors received warrants to purchase up to 350,000 shares of common stock at an initial exercise price of $1.00 per share, exercisable immediately and expiring after up to five years or upon certain corporate events. The securities were sold in a private placement relying on exemptions under Section 4(a)(2) and Rule 506 of Regulation D.
Jaguar Health, Inc. filed an amended current report to correct dates in a prior disclosure and to fully restate the terms of a recent financing. On January 6, 2026, the company entered into securities purchase agreements with two accredited investors and issued $350,000 aggregate principal amount of unsecured promissory notes, with proceeds to be used for working capital and other general corporate purposes. The notes bear 6% annual interest, mature one month after issuance, and may be prepaid without penalty. As an inducement, the investors also received warrants to purchase up to 350,000 shares of common stock at an initial exercise price of $1.00 per share, exercisable immediately and expiring upon the earliest of five years from issuance, a fundamental transaction, or a liquidation event.
Jaguar Health, Inc. entered into securities purchase agreements with two accredited investors, issuing $350,000 aggregate principal amount of unsecured promissory notes to raise funds for working capital and other general corporate purposes. The notes bear 6% annual interest and mature one month after issuance, and may be prepaid at any time without penalty.
As an inducement, the investors received warrants to purchase up to 350,000 shares of common stock at an initial exercise price of $1.00 per share, exercisable immediately and expiring on the earlier of five years from issuance, a fundamental transaction, or a liquidation event. The securities were issued in a private offering relying on exemptions under Section 4(a)(2) and Rule 506 of Regulation D.
Jaguar Health Chief Scientific Officer Pravin Chaturvedi reported new equity awards in the company’s stock. On December 11, 2025, he received 11,740 restricted stock units, each representing a right to one share of Jaguar Health voting common stock. These restricted stock units vest on December 11, 2026, when the underlying shares are scheduled to be delivered.
On the same date, he was also granted a stock option covering 11,740 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests ratably on a monthly basis over 12 months from the grant date, as long as he remains employed, and both awards were granted under Jaguar Health’s 2014 Stock Incentive Plan. Following the grant, he beneficially owned 11,938 shares of common stock directly, plus the 11,740 stock options. The filing also notes a 25-for-1 reverse stock split of Jaguar’s voting common stock effective March 24, 2025.
Jaguar Health director James J. Bochnowski reported new equity awards. On December 11, 2025, he received 6,363 restricted stock units and a stock option for 6,363 shares of common stock, granted under the company’s 2014 Stock Incentive Plan.
Each restricted stock unit represents one share of voting common stock and will vest on December 11, 2026, with shares delivered on that date. The stock option has an exercise price of $1.44 per share, vests ratably on a monthly basis over 12 months from the grant date while he continues serving on the board, and expires on December 11, 2035.
Following the grant, Bochnowski beneficially owned 6,415 shares of Jaguar Health common stock directly.
Jaguar Health director Jonathan B. Siegel reported receiving new equity awards under the company’s 2014 Stock Incentive Plan. The filing shows 7,377 restricted stock units and a stock option covering 7,377 shares of common stock, both granted on 12/11/2025 at no cost for the awards themselves, with the option carrying a $1.44 exercise price and expiring on 12/11/2035.
The restricted stock units are scheduled to vest on 12/11/2026, while the options vest ratably on a monthly basis over 12 months from the grant date, contingent on his continued board service at Jaguar Health and its subsidiary Napo Therapeutics, S.p.A. Following these grants, he directly beneficially owned 7,423 shares of Jaguar Health common stock.
Jaguar Health, Inc. director Anula Jayasuriya received equity awards consisting of 5,870 restricted stock units and stock options covering 5,870 shares of common stock, approved by the board on December 11, 2025 under the company’s 2014 Stock Incentive Plan.
Each restricted stock unit represents a right to receive one share and vests on December 11, 2026, while the options have a $1.44 exercise price, vest monthly over 12 months from the grant date, and expire on December 11, 2035. Following these grants, she beneficially owns 5,916 shares of common stock and 5,870 stock options, held directly.
Jaguar Health, Inc. reported that its Chief Financial Officer, Carol R. Lizak, received new equity awards on December 11, 2025.
The awards include 11,740 restricted stock units, each representing a contingent right to receive one share of voting common stock for $0 consideration, with beneficial ownership of common stock reported as 11,911 shares after the transaction. She also received stock options to purchase 11,740 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035.
The grants were made under the company’s 2014 Stock Incentive Plan. The restricted stock units vest on December 11, 2026, and vested shares will be delivered on that vesting date, while the options vest in equal monthly installments over 12 months from the grant date, subject to continued employment.